Melanoma Clinical Trials in Pittsburgh, Pennsylvania

15 studies are recruiting for melanoma in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

2. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

   This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   111 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06246916 on ClinicalTrials.gov

3. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

   A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Pittsburgh, Pennsylvania

   Locations

   13 in total

   Run by

   AstraZeneca

   See if you can join NCT07115043 on ClinicalTrials.gov

4. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

   This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh, Pennsylvania

   Locations

   10 in total

   Run by

   Obsidian Therapeutics, Inc.

   See if you can join NCT06060613 on ClinicalTrials.gov

5. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

   This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Allegheny Health Network, Pittsburgh, Pennsylvania

   Locations

   81 in total

   Run by

   Iovance Biotherapeutics, Inc.

   See if you can join NCT05727904 on ClinicalTrials.gov

6. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

   Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Dan Zandberg

   See if you can join NCT04114136 on ClinicalTrials.gov

7. Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

   Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and disease characteristics, including the location and number of ITMs presents a barrier to a one size …

   Stage

   Not phased

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Yana Najjar

   See if you can join NCT04658303 on ClinicalTrials.gov

8. Evaluation of Hypoxia in Primary Melanoma

   When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumors may be utilizing deregulated metabolism as a means of propagating themselves to the next station…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Yana Najjar

   See if you can join NCT06831071 on ClinicalTrials.gov

9. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

   This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   11 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06413680 on ClinicalTrials.gov

10. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Locations

    23 in total

    Run by

    Nested Therapeutics, Inc

    See if you can join NCT06326411 on ClinicalTrials.gov

11. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Diwakar Davar

    See if you can join NCT07223424 on ClinicalTrials.gov

12. RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

    This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, in…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Yana Najjar

    See if you can join NCT06216938 on ClinicalTrials.gov

13. Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

    This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented me…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    John Kirkwood

    See if you can join NCT06599619 on ClinicalTrials.gov

14. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

    Locations

    9 in total

    Run by

    ImmVira Pharma Co. Ltd

    See if you can join NCT04370587 on ClinicalTrials.gov

15. Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the un…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Locations

    4 in total

    Run by

    CJ Bioscience, Inc.

    See if you can join NCT05877430 on ClinicalTrials.gov